Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., the holding subsidiary of the company, was approved by the State Drug Administration for drug registration application for new indications of ruvometinib tablets (trade name: fumainine, project code: FCN-159). The new approved indications are for adult patients with neurofibromatosis type I (NF1) with symptoms and inoperable plexiform neurofibromatosis (PN).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.